Advanced search
Publication Cover
Expert Review of Vaccines Volume 12, 2013 - Issue 9
Submit an article Journal homepage
399
Views
45
CrossRef citations to date
0
Altmetric
Reviews

Increasing rates of Salmonella Paratyphi A and the current status of its vaccine development

Sushant SahastrabuddheInternational Vaccine Institute, San 4-8, Nakseongdae-dong, Gwanak-gu, Seoul, 151-919, Korea
,
Rodney CarbisInternational Vaccine Institute, San 4-8, Nakseongdae-dong, Gwanak-gu, Seoul, 151-919, Korea
,
Thomas F WierzbaInternational Vaccine Institute, San 4-8, Nakseongdae-dong, Gwanak-gu, Seoul, 151-919, Korea
&
R Leon OchiaiInternational Vaccine Institute, San 4-8, Nakseongdae-dong, Gwanak-gu, Seoul, 151-919, Korea
Pages 1021-1031 | Published online: 09 Jan 2014

References

  • Levine MM. Typhoid fever vaccines. In: Vaccines. Orenstein SA, Plotkin WA ( Eds). WB Saunders Company, Philadelphia, USA 781–814 (1999).
  • Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet 366(9487), 749–762 (2005).
  • Crump JA, Luby LP, Mintz ED. The global burden of typhoid fever. Bull. World Health Organ. 82 (5), 346–353 (2004).
  • World Health Organization. Background document: The diagnosis, treatment and prevention of typhoid fever. Background document: The diagnosis, treatment and prevention of typhoid fever (2003).
  • Verma S, Thakur S, Kanga A, Singh G, Gupta P. Emerging Salmonella Paratyphi A enteric fever and changing trends in antimicrobial resistance pattern of salmonella in Shimla. Indian J. Med. Microbiol. 28(1), 51–53 (2010).
  • Saqib A, Ahmed A. Culture and sensitivity of salmonella species: Analysis of a two year data. J. Pak. Med. Assoc. 97(8), 282–284 (2000).
  • Karkey A, Aryjal A, Basnyat B, Baker S. Kathmandu, Nepal: Still an enteric fever capital of the world. 2(6), 461–465 (2008).
  • Karkey A, Arjyal A, Anders KL et al. The burden and characteristics of enteric fever at a healthcare facility in a densely populated area of kathmandu. PLoS One 5(11), e13988 (2010).
  • Woods CW, Murdoch DR, Zimmerman MD et al. Emergence of Salmonella enterica serotype Paratyphi A as a major cause of enteric fever in Kathmandu, Nepal. Trans. R. Soc. Trop. Med. Hyg. 100(11), 1063–1067 (2006).
  • Jin Y. Enteric Fever in South China: Guangxi Province. J. Infect. Dev. Ctries. 30(2(4)), 283–288 (2008).
  • Ochiai R, Wang X, Von Seidlein L et al. Salmonella Paratyphi A Rates, Asia. Emerg. Infect. Dis. 11(11), 1764–1766 (2005).
  • Saxena SN, Sen R. Salmonella paratyphi A infection in India: incidence and phage types. Trans. R. Soc. Trop. Med. Hyg. 60(3), 409–411 (1966).
  • Mendiratta DK, Deotale V, Thamke D, Narang R, Narang P. Enteric fever due to S. paratyphia - an emerging problem. Indian. J. Med. Microbiol. 22(3):196 (2004).
  • Connor BA, Schwartz E. Typhoid and paratyphoid fever in travellers. Lancet Infect. Dis. 5(10), 623–628 (2005).
  • Chalkias A, Anastasopoulos D, Tsiaglis S.Enteric fever due to Salmonella Paratyphi A in Greece: a case report. Cases J. 1(1), 403 (2008).
  • Laupland K, Schonheyder H, Kennedy K et al. Salmonella enterica bacteraemia: a multi-national population-based cohort study. BMC Infect. Dis. 10(1), 95 (2010).
  • Boggild AK, Castelli F, Gautret P et al. Vaccine preventable diseases in returned international travelers: Results from the GeoSentinel Surveillance Network. Vaccine 28(46), 7389–7395 (2010).
  • Abucejo PE, Capeding MR, Lupisan SP et al. Blood culture confirmed typhoid fever in a provincial hospital in the Philippines. Southeast Asian J. Trop. Med. Public Health 32, 531–536 (2001).
  • Sood SKA, Dash N, Das Bk, Goel V, Seth P. Paratyphoid fever in India: An Emereging Problem. Emerg. Infect. Dis. 5(3), 483–484 (1999).
  • Threlfall EJ, Fisher IST, Berghold C et al. Trends in antimicrobial drug resistance in Salmonella enterica serotypes Typhi and Paratyphi A isolated in Europe, 1999–2001. Int. J. Antimicrob. Agents 22(5), 487–491 (2003).
  • Bhatta DR, Bangtrakulnonth A, Tishyadhigama P et al. Serotyping, PCR, phage-typing and antibiotic sensitivity testing of Salmonella serovars isolated from urban drinking water supply systems of Nepal. Lett. Appl. Microbiol. 44(6), 588–594 (2007).
  • Gupta V, Kaur J, Chander J. An increase in enteric fever cases due to Salmonella Paratyphi A in & around Chandigarh. Indian J. Med. Res. 129(1), 95–98 (2009).
  • Mandal S, Mandal MD, Pal NK. Antibiotic resistance of Salmonella enterica serovar Paratyphi A in India: emerging and reemerging problem. J. Postgrad. Med. 52(3), 163–166 (2006).
  • Mohanty S, Renuka K, Sood S, Das BK, Kapil A. Antibiogram pattern and seasonality of Salmonella serotypes in a North Indian tertiary care hospital. Epidemiol. Infect. 134(5), 961–966 (2006).
  • Mahanta J. Drug sensitivity of Salmonella paratyphi A isolated from a suspected outbreak of enteric fever in Duliajan. J. Indian Med. Assoc. 92(2), 49–50 (1994).
  • Parry CM, Threlfall E. Antimicrobial resistance in typhoidal and nontyphoidal salmonellae. Curr. Opin. Infect. Dis. 21(5), 531–538 510.1097/QCO.1090b1013e32830f32453a (2008).
  • Padma Krishnan MS, Balasubramanian S. Changing trends in antimicrobial resistance of Salmonella enterica serovar typhi and salmonella enterica serovar paratyphi A in Chennai. Indian J. Pathol Microbiol. 52(4), 505–508 (2009).
  • Olopoenia LA, King AL. Widal agglutination test 100 years later: still plagued by controversy. Postgrad. Med. J. 76(892), 80–84 (2000).
  • Parry CM, Wijedoru L, Arjyal A, Baker S. The utility of diagnostic tests for enteric fever in endemic locations. Expert Rev. Anti Infect. Ther. 9(6), 711–725 (2011).
  • Gasem MH, Dolmans WM, Isbandrio BB, Wahyono H, Keuter M, Djokomoeljanto R. Culture of Salmonella typhi and Salmonella paratyphi from blood and bone marrow in suspected typhoid fever. Trop. Geograph. Med. 47(4), 164–167 (1995).
  • Yu F, Fan S, Fan X et al. Analysis of characteristics of paratyphoid A in 157 Chinese inpatients between 1998 and 2009. Eur. J. Clin. Microbiol. Infect. Dis. 30(1), 71–75 (2011).
  • Chart H, Cheasty T, Dec Pinna E et al. Serodiagnosis of Salmonella enterica serovar Typhi and S. enterica serovars Paratyphi A, B and C human infections. J. Med. Microbiol. 56(Pt 9), 1161–1166 (2007).
  • Naheed A, Ram PK, Brooks WA et al. Burden of typhoid and paratyphoid fever in a densely populated urban community, Dhaka, Bangladesh. Int. J. Infect. Dis. 14(Suppl. 3), e93–e99 (2010).
  • Vollaard AM, Ali S, Van Asten HA et al. Risk Factors for Typhoid and Paratyphoid Fever in Jakarta, Indonesia. JAMA 291(21), 2607–2615 (2004).
  • Pearson RD. Guerrant R. Enteric fever and other causes of abdominal symptoms with fever. Churchill Livingstone, New York 998–1012 (1995).
  • Crump JA, Mintz ED. Global Trends in Typhoid and Paratyphoid Fever. Clin. Infect. Dis. 50(2), 241–246 (2010).
  • Christie AB. Infectious Diseases: Epidemiology and Clinical Practice. Churchill Livingstone, New York (1987).
  • Maskey AP, Day JN, Tuan PQ et al. Salmonella enterica Serovar Paratyphi A and S. enterica Serovar Typhi cause indistinguishable clinical syndromes in Kathmandu, Nepal. Clin. Infect. Dis. 42(9), 1247–1253 (2006).
  • Pandit A, Arjyal A, Paudyal B et al. A Patient with paratyphoid a fever: an emerging problem in asia and not always a benign disease. J. Travel Med. 15(5), 364–365 (2008).
  • Pancharoen CTC, Thisyakorn U. Endocarditis and pericarditis caused by Salmonella paratyphi A: two case reports and review of the literature. Southeast Asian J. Trop. Med. Public Health 33 (1), 161–163 (2002).
  • Kudalkar D, Thermidor M, Cunha BA. Salmonella paratyphi a enteric fever mimicking viral meningitis. Heart Lung33(6), 414–416 (2004).
  • Bhooshan P, Shivaprakasha S, Dinesh KR, Kiran M, Karim P. Chronic subdural empyema and cranial vault osteomyelitis due to Salmonella paratyphi A. Indian J. Med. Microbiol. 28(1), 60–62 (2010).
  • Khan FY, Kamha AA, Alomary IY. Fulminant hepatic failure caused by Salmonella paratyphi A infection. World J. Gastroenterol. 12 (32), 5253–5255 (2006).
  • Matar IM, Rashed AH, Nyman Ur. Salmonella liver abscess. Trans. R. Soc. Trop. Med. Hyg. 84, 431–432 (1990).
  • Sanjay D'cruz SK, Sandeep Chauhan, Varsha Gupta. Isolation of Salmonella paratyphi A from renal abscess. Indian J. Pathol. Microbiol. 52(1), 117–119 (2009).
  • Navin P, Thambu DS, Venugopal R, Subhash HS, Thomas K. Salmonella paratyphi osteomyelitis and psoas abscess. Trop. Doc. 36(1), 58–59 (2006).
  • Fule RP, Saoji AM. Isolation of Salmonella paratyphi A from thyroid abscess – a case report. Indian J. Med. Sci. 43, 95–96 (1989).
  • Chiva Lm, Ergeneli M, Santisteban J. Salmonella abscess of the ovary. Am. J. Obstr. Gynecol. 172, 215–216 (1995).
  • Sinha S, Sharma DC, Miri B, Gupta V, Chattopadhyay Tk. Splenic abscess – case report and review of literature. Trop. Gastroenterol. 18, 134–135 (1997).
  • Meltzer E, Sadik C, Schwartz E. Enteric fever in Israeli travelers: a nationwide study. J. Travel Med. 12(5), 275–281 (2005).
  • Luby SP, Faizan MK, Fisher-Hoch SP et al. Risk factors for typhoid fever in an endemic setting, Karachi, Pakistan. Epidemiol. Infect. 120(02), 129–138 (1998).
  • Khan MI, Ochiai RL, Soofi SB et al. Risk factors associated with typhoid fever in children aged 2–16 years in Karachi, Pakistan. Epidemiol. Infect. FirstView, 1–8 (2011).
  • Ekdahl K, de Jong B, Andersson Y. Risk of travel-associated typhoid and paratyphoid fevers in various regions. J. Travel Med. 12, 197–204 (2005).
  • Sinha A, Sazawal S, Kumar R et al. Typhoid fever in children aged less than 5 years. Lancet 354(9180), 734–737 (1999).
  • Reed RP, Klugman KP. Neonatal typhoid fever. Pediatr. Infect. Dis. J. 13(9), 774–777 (1994).
  • Raveendran RWC, Sharma A, Kler N, Garg P, Gujral K, Khera N. Vertical transmission of Salmonella Paratyphi A. Indian J. Pediat. 74(8), 784–786 (2007).
  • Kumar A, Chadha R, Randhawa V. Vertical transmission of Salmonella paratyphi A. Indian J. Pediat. 75(9), 964–965 (2008).
  • Bahl R, Sinha A, Poulos C et al. Costs of illness due to typhoid fever in an Indian urban slum community: implications for vaccination policy. J. Health Popul. Nutr. 22(3), 304–310 (2004).
  • Wright AE, Semple D. On the employment of dead bacteria in the serum diagnosis of typhoid and malta fever, and on an easy method of extemporising a blowpipe flame for making capillary sero-sedimentation tubes. Br. Med. J. 1(1898), 1214–1215 (1897).
  • Stuhl L, Benda R, Frey N. A controled field trial of the effectiveness of acetone-dried and inactivated and heat-phenol-inactivated typhoid vaccines in yugoslavia. Bull. World Health Organ. 30, 623–630 (1964).
  • Ashcroft MT, Ritchie JM, Nicholson CC. Controlled field trial in British guiana school children of heat-killed-phenolized and acetone-killed lyophilized typhoid vaccines. Am. J. Hyg. 79, 196–206 (1964).
  • Ashcroft MT, Ritchie JM, Nicholson CC, Stuart CA. Antibody responses to vaccination of British Guiana school children with heart-killed-phenolized and acetone-killed lyophilized typhoid vaccines. Am. J. Hyg. 80, 221–228 (1964).
  • Wahdan MH, Sippel JE, Mikhail IA et al. Controlled field trial of a typhoid vaccine prepared with a nonmotile mutant of Salmonella typhi Ty2. Bull. World Health Organ. 52(1), 69–73 (1975).
  • Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. Bull. World Health Organ. 72(6), 957–971 (1994).
  • Engels EA, Lau J. Vaccines for preventing typhoid fever. Cochrane Database Syst. Rev. 2 (2000).
  • Longfellow D, Luippold GF. Typhoid Vaccine Studies VII: Typhoid-Paratyphoid Vaccine. Am. J. Public Health Nations Health 33(5), 561–568 (1943).
  • Hejfec LB, Levina LA, Kuz'minova ML, Salmin LV, Slavina AM, Vasil'eva AV. Controlled field trials of paratyphoid B vaccine and evaluation of the effectiveness of a single administration of typhoid vaccine. Bull. World Health Organ. 38(6), 907–915 (1968).
  • Hejfec LB, Levina LA, Kuz'minova ML et al. Controlled field trial with dried sorbed paratyphoid B and typhoid vaccines. Bull. World Health Organ. 45(6), 787–794 (1971).
  • Levine MM, Ferreccio C, Black RE, Lagos R, Martin OS, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin. Infect. Dis. 45(Suppl. 1), S24–S28 (2007).
  • Schwartz E, Shlim DR, Eaton M, Jenks N, Houston R. The effect of oral and parenteral typhoid vaccination on the rate of infection with Salmonella typhi and Salmonella paratyphi A among foreigners in Nepal. Arch. Intern. Med. 150(2), 349–351 (1990).
  • Simanjuntak CH, Paleologo FP, Punjabi NH et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 338(8774), 1055–1059 (1991).
  • Meltzer E, Schwartz E. Enteric fever: a travel medicine oriented view. Curr. Opin. Infect. Dis. 23(5), 432–437 (2010).
  • Wahid R, Simon R, Zafar SJ, Levine MM, Sztein MB. Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans. Clin. Vaccine Immunol. 19(6), 825–834 (2012).
  • Pakkanen SH, Kantele JM, Kantele A. Cross-reactive gut-directed immune response against Salmonella enterica serovar Paratyphi A and B in typhoid fever and after oral Ty21a typhoid vaccination. Vaccine 30(42), 6047–6053 (2012).
  • Levine M. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol 8(129), 1741–7007 (2010).
  • Curtiss R, 3rd, Wanda SY, Gunn B. M et al. Salmonella enterica serovar typhimurium strains with regulated delayed attenuation in vivo. Infect. Immun. 77(3), 1071–1082 (2009).
  • Roland KL, Tinge SA, Kochi SK, Thomas LJ, Killeen K. Reactogenicity and immunogenicity of live attenuated Salmonella enterica serovar Paratyphi A enteric fever vaccine candidates. Vaccine 28(21), 3679–3687 (2010).
  • Hohmann EL, Oletta CA, Killeen KP, Miller S. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. 173(6), 1408–1414 (1996).
  • Hohmann EL, Oletta CA, Miller SI. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine 14(1), 19–24 (1996).
  • Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun. 68(4), 2135–2141 (2000).
  • Nih U. Safety and Immunogenicity of CVD 1902 oral attenuated vaccine to prevent S. paratyphi A infection. Infection (2013).
  • Gat O, Galen JE, Tennant S et al. Cell-associated flagella enhance the protection conferred by mucosally administered attenuated Salmonella Paratyphi A vaccines. PLoS Negl. Trop. Dis. 5(11), 1 (2011).
  • Eskola J, Kayhty H, Peltola H et al. Antibody levels achieved in infants by course of Haemophilus influenzae type B polysaccharide/diphtheria toxoid conjugate vaccine. Lancet 1(8439), 1184–1186 (1985).
  • Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 29(41), 7207–7211 (2011).
  • Duggan S. T. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13(R)]. Drugs 70(15), 1973–1986 (2010).
  • Jennings HJ, Lugowski C, Ashton FE. Conjugation of meningococcal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as route to a potential vaccine against group B Neisseria meningitidis. Infect. Immun. 43(1), 407–412 (1984).
  • Rondini S, Micoli F, Lanzilao L, Hale C, Saul AJ, Martin LB. Evaluation of the immunogenicity and biological activity of the citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica Serovar Typhi. Clin. Vaccine Immunol. 18(3), 460–468 (2011).
  • Ali A, An SJ, Cui C, Haque A, Carbis R. Preparation and evaluation of immunogenic conjugates of Salmonella enterica serovar Typhi O-specific polysaccharides with diphtheria toxoid. Hum. Vaccin. Immunother. 8(2), 189–193 (2012).
  • An SJ, Yoon YK, Kothari S et al. Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity. Vaccine 29(44), 7618–7623 (2011).
  • An SJ, Yoon YK, Kothari S et al. Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine. Vaccine 30(6), 1023–1028 (2012).
  • Cui C, Carbis R, An SJ et al. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates. Clin. Vaccine Immunol. 17(1), 73–79 (2010).
  • Micoli F, Rondini S, Pisoni I et al. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. Vaccine 29(4), 712–720 (2011).
  • Rondini S, Micoli F, Lanzilao L et al. Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM197 glycoconjugate vaccine against Salmonella Typhi. J. Infect. Dev. Ctries. 6(11), 763–773 (2012).
  • Fiorino F, Ciabattini A, Rondini S, Pozzi G, Martin LB, Medaglini D. Immunization with the conjugate vaccine Vi-CRM(1)(9)(7) against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice. Vaccine 30(43), 6111–6114 (2012).
  • Thiem VD, Lin FY, Canh Do G et al. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin. Vaccine Immunol. 18(5), 730–735 (2011).
  • Van Damme P, Kafeja F, Anemona A et al. Safety, immunogenicity and dose ranging of a new Vi-CRM(1)(9)(7) conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS One 6(9), 30 (2011).
  • Martin LB. Vaccines for typhoid fever and other salmonelloses. Curr. Opin. Infect. Dis. 25(5), 489–499 (2012).
  • Colwell DE, Michalek SM, Briles DE, Jirillo E, Mcghee JR. Monoclonal antibodies to Salmonella lipopolysaccharide: anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent Salmonella typhimurium. J. Immunol. 133(2), 950–957 (1984).
  • Robbins JB, Chu C, Schneerson R. Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin. Infect. Dis. 15(2), 346–361 (1992).
  • Svenson SB, Lindberg AA. Artificial Salmonella vaccines: Salmonella typhimurium O-antigen-specific oligosaccharide-protein conjugates elicit protective antibodies in rabbits and mice. Infect. Immun. 32(2), 490–496 (1981).
  • Watson DC, Robbins JB, Szu SC. Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect. Immun. 60(11), 4679–4686 (1992).
  • Konadu E, Shiloach J, Bryla DA, Robbins JB, Szu SC. Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls. Infect. Immun. 64(7), 2709–2715 (1996).
  • Kohn J, Wilchek M. 1-Cyano-4-dimethylamino pyridinium tetrafluoroborate as a cyanylating agent for the covalent attachment of ligand to polysaccharide resins. FEBS Lett. 154(1), 209–210 (1983).
  • Konadu EY, Lin F-YC, Hó VA et al. Phase 1 and Phase 2 Studies of Salmonella enterica Serovar Paratyphi A O-Specific Polysaccharide-Tetanus Toxoid Conjugates in Adults, Teenagers, and 2- to 4-Year-Old Children in Vietnam. Infect. Immun. 68(3), 1529–1534 (2000).
  • Min Q, Guo-You Y, Xiao-Ping TU et al. Preparation, safety and immunogenicity of s. paratyphoid a-tetanus toxoid conjugate vaccine. China J. Biol. 19(6), 594–596 (2006).
  • Zhao Zi-Qiang YZ-H, Yong-Li J, Lin D, Gui-Lin X. Synthesis and immunogenicity in mice of conjugate vaccine of Salmonella paratyphi A O-SP bound to Tetanus Toxoid. China J. Microbiol. Immunol. 26(11), 1048–1052 (2006).
  • Dai Chang-Hai BC, Fei H. The function of of S. paratyphoid A-tetanus toxoid's immunity enhancement to the detoxified lipopolysaccharide. Chinese J. Pract. Med. 6(7), 17–18 (2011).
  • Zhai Jing ZLJ, Cheng LZ, Guang LW, Jie WY, Tang GM. Long term toxicity of intramuscularly injected paratyphoid A polysaccharide protein binding vaccine in rats. Chinese J. N. Drugs 18(19), 1860–1864 (2009).
  • Group CNB. Lanzhou Institute successfully completes the first round of vaccination of phase II clinical trial of paratyphi A conjugate vaccine. Lanzhou Institute successfully completes the first round of vaccination of phase II clinical trial of paratyphi A conjugate vaccine ( 31/01/2013) (2012).
  • S. Kothari Kim JA, Kothari N, Carbis R. Process development of an affordable bivalent conjugate vaccine against the two major causes of enteric fever, Salmonella typhi and Salmonella paratyphi A. Process development of an affordable bivalent conjugate vaccine against the two major causes of enteric fever, Salmonella typhi and Salmonella paratyphi A (31/01/2013)(2011).
  • Micoli F, Rondini S, Gavini M et al. O:2-CRM(197) conjugates against Salmonella Paratyphi A. PLoS One 7(11), 7 (2012).
  • Micoli F, Rondini S, Gavini M et al. A scalable method for O-antigen purification applied to various Salmonella serovars. Anal. Biochem. 434(1), 136–145 (2013).
  • Path. Revolutionary meningitis vaccine breaks another barrier; first to gain approval to travel outside cold chain. Revolutionary meningitis vaccine breaks another barrier; first to gain approval to travel outside cold chain (2012).
  • Tankhiwale SS, Agrawal G, Jalgaonkar SV. An unusually high occurrence of Salmonella enterica serotype paratyphi A in patients with enteric fever. Indian J. Med. Res. 117, 10–12 (2003).
  • Padmapriya V, Kenneth J, Amarnath SK. Re-emergence of Salmonella paratyphi A: a shift in immunity? Natl. Med. J. India. 16(1):47–48 (2003).
  • Palit A, Ghosh S, Dutta S, Sur D, Bhattacharya MK, Bhattacharya SK. Increasing prevalence of Salmonella enterica serotype Paratyphi-A in patients with enteric fever in a periurban slum setting of Kolkata, India. Int. J. Environ. Health Res. 16(6), 455–459 (2006).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.